GlassScriptPhysician profile
Andrews Paul
NPI 1780656249
$6,464.19
in general payments reported to CMS, 2019-2025
32 companies · $1,641 in 2025
The $1,641 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,661 · 2020: $160 · 2021: $401 · 2022: $499 · 2023: $1,440 · 2024: $661 · 2025: $1,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,542 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,542.08 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,567.66 | 2019-2025 | Tezspire, Fasenra |
| Amgen INC. | $587.08 | 2023-2025 | Tezspire |
| Janssen Pharmaceuticals, INC | $530.93 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $363.59 | 2019-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $290.18 | 2023-2025 | Lumryz |
| Axsome Therapeutics, INC. | $284.71 | 2023-2025 | Sunosi |
| Alexion Pharmaceuticals, INC. | $246.30 | 2023 | Ultomiris |
| Pfizer INC. | $242.22 | 2020-2024 | |
| Inari Medical, INC. | $221.62 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.90 | 2019 | |
| Electromed, INC. | $160.00 | 2019 | |
| Genentech USA, INC. | $148.28 | 2019 | |
| Abbott Laboratories | $145.99 | 2025 | 2nd Gen Centrimag Primary Console |
| Tactile Systems Technology INC | $145.63 | 2024 | Flexitouch Plus, Entre Plus |
| 3b Medical, INC. | $134.48 | 2024 | Luna |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $121.83 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $118.33 | 2024-2025 | Dupixent |
| Galvanize Therapeutics, INC | $115.58 | 2025 | Aliya System |
| Ucb, INC. | $113.84 | 2022-2023 | Briviact |
| Philips North America LLC | $103.06 | 2019 | |
| Breas Medical, INC. | $93.32 | 2025 | Vivo 45 Ls, Human Design Medical, Vivo 1/2 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $85.42 | 2021 | |
| Mylan Specialty L.P. | $83.59 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $82.76 | 2019 | |
| Allergan, INC. | $77.46 | 2020 | |
| Insmed, INC. | $68.97 | 2019 | |
| Grifols USA, LLC | $37.01 | 2019-2020 | |
| Advanced Respiratory, INC | $21.25 | 2019 | |
| Cequr Corporation | $20.10 | 2023 | Cequr Simplicity |
| Inogen, INC. | $17.67 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.98 | 2019 | |
| Edwards Lifesciences Corporation | $15.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrews Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.